I want to ...

Clinical Trials


In cancer research, a clinical trial is an organized study conducted among people with cancer to answer specific questions about a new treatment or new way of using a known treatment.

Each study tries to increase medical knowledge and find new and better ways to help patients with cancer.

The decision to participate in a clinical trial is an important one.

The National Institutes of Health provides information to help guide patients in their decision.

Besides studying new anticancer drugs, clinical trials study new combinations of drugs already used in cancer treatment, new ways of providing treatment and how lifestyle changes can help cancer patients or prevent cancer from occurring.

Other trials compare the best known standard therapy with a newer therapy to see if one produces more cures and causes fewer side effects than the other.

Through our partnership with Eastern Maine Medical Center, the Harold Alfond Center for Cancer Care offers patients access to many of the same cutting-edge research studies and experimental medications that are used at the top cancer centers throughout the country.

Unless indicated as closed, the following clinical trials are open to enrollment.

For more information about MaineGeneral's ongoing clinical trials, please call (207) 626-4855 or (207) 626-4806.

Updated May 19, 2015

Trials by Site
Protocol Name
  ​   ​
​Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab versus Bevacizumab in Bevacizumab Naïve Patients with Recurrent Glioblastoma Multiforme
Breast SWOG 1107 ​A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes Hormone Receptor Positive and HER2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

SWOG 1207

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant EndocrineTherapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor Positive and HER2/NEU Negative Breast Cancer


A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

SWOG S1202

A Randomized Placebo-Controlled Phase III Study of Duloxetine for Women with Early Stage Breast Cancer


Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study

ECOG E2112

A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer


A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-Center Phase III Study to Assess the Efficacy and Safety of Olaparib vs Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Parimary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy


CALGB C80702

A Phase III Trial of 6 vs. 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

SWOG S1406 ​Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Colorectal Cancer
SWOG S0931 ​EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy: A Phase III Study
SWOG S1216 ​A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Alliance A031201 ​Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
RTOG 0924 * ​Androgren Deprivation Therapy and High-Dose Radiotherapy with or without Whole Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial
Leukemia SWOG S1203
​A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) vs. IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
A041202 ​A Randomized Phase III Study of Bendamustine Plus Rituximab vs. Ibrutinib Plus Rituximab vs. Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
ECOG E1912 ​A Randomized Phase IIII Study of Ibrutinib (PCI-32765)-Based Therapy vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Lung RTOG 1306
​A Randomized Phase II Study of Individualized Combined Modality Therapy For Stage III Non-Small Cell Lung Cancer (NSCLC)
SWOG S1400 ​A Phase II/III Biomarker Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
A151216 ALCHEMIST ​Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
ECOG E4512 ​A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A081105 ​Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

NRG-LU001 * ​Randomized Phase II Trial Of Concurrent Chemoradiotherapy +/- Metformin HCL In Locally Advanced NSCLC
E2511 ​Phase I and Randomized Phase II Double-Blind Clinical Trial of Veliparib (ABT-883) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Lymphoma CALGB 50904 ​A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC# 681239, IND# 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma
ECOG E1411
​Intergroup Randomized Phase II Four Arm Study in Patients >60 with Previously Untreated Mantle Cell Lymphoma of Therapy With: Arm A = Rituximab + Bendamustine Followed by Rituximab Consolidation (RB→R); Arm B = Rituximab + Bendamustine + Bortezomib Followed by Rituximab Consolidation (RBV→R); Arm C = Rituximab + Bendamustine Followed by Lenalidomide + Rituximab Consolidation (RB→LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed by Lenalidomide + Rituximab Consolidation (RBV→LR)
ECOG 1412 ​Randomized Phase II Open Label Study of Lenalidomide vs. R-Chop (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Melanoma E3612 ​A Randomized Phase II Trial of Ipilimumab with or Without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma
Myeloma ECOG E1A11 ​Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) vs. Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
SWOG S1304 ​S1304 A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease

* = Pending Radiation Oncology credential